Evaxion Biotech Research Development Over Time
| EVAX Stock | USD 1.66 0.09 5.73% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Evaxion Biotech Performance and Evaxion Biotech Correlation. Evaxion |
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Evaxion Biotech. If investors know Evaxion will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Evaxion Biotech listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.80) | Revenue Per Share 0.713 | Return On Assets (0.69) | Return On Equity (8.03) |
The market value of Evaxion Biotech AS is measured differently than its book value, which is the value of Evaxion that is recorded on the company's balance sheet. Investors also form their own opinion of Evaxion Biotech's value that differs from its market value or its book value, called intrinsic value, which is Evaxion Biotech's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Evaxion Biotech's market value can be influenced by many factors that don't directly affect Evaxion Biotech's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Evaxion Biotech's value and its price as these two are different measures arrived at by different means. Investors typically determine if Evaxion Biotech is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Evaxion Biotech's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Cross Equities Research Development Analysis
Compare Evaxion Biotech AS and related stocks such as Sigilon Therapeutics, Reviva Pharmaceuticals, and ZyVersa Therapeutics Research Development Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| RVPH | 195.7 K | 195.7 K | 195.7 K | 195.7 K | 195.7 K | 195.7 K | 195.7 K | 195.7 K | 195.7 K | 195.7 K | 295.1 K | 4.9 M | 18.9 M | 31.4 T | 33 T |
| ZVSA | 6.5 M | 6.5 M | 6.5 M | 6.5 M | 6.5 M | 6.5 M | 6.5 M | 6.5 M | 6.5 M | 6.5 M | 6.5 M | 2.1 M | 5.4 M | 3.2 M | 3.4 M |
| UNCY | 795 K | 795 K | 795 K | 795 K | 795 K | 795 K | 795 K | 795 K | 795 K | 795 K | 1 M | 6.1 M | 12.4 M | 12.9 M | 7.3 M |
| QNRX | 8.3 M | 8.3 M | 8.3 M | 8.3 M | 8.3 M | 8.3 M | 8.3 M | 5.9 M | 8.3 M | 45.6 K | 244.2 K | 1.6 M | 2.7 M | 3.2 M | 3 M |
| ALLR | 6.4 M | 6.4 M | 6.4 M | 6.4 M | 6.4 M | 6.4 M | 6.4 M | 6.4 M | 6.4 M | 6.4 M | 5.1 M | 14.2 M | 6.9 M | 7.9 M | 8.9 M |
| VRAX | 87 K | 87 K | 87 K | 87 K | 87 K | 87 K | 87 K | 87 K | 87 K | 87 K | 120.2 K | 433.7 K | 397.1 K | 1.6 M | 1.6 M |
| BDRX | 1.7 M | 1.7 M | 1.7 M | 2.8 M | 5.4 M | 8.7 M | 7.7 M | 9.8 M | 9.4 M | 7.8 M | 16.1 M | 4.7 M | 5.1 M | 4.1 M | 7.6 M |
| LYEL | 63.6 M | 63.6 M | 63.6 M | 63.6 M | 63.6 M | 63.6 M | 63.6 M | 63.6 M | 63.6 M | 63.6 M | 182.2 M | 138.7 M | 159.2 M | 182.9 M | 159.9 M |
| CGEM | 8.7 K | 8.7 K | 8.7 K | 8.7 K | 8.7 K | 9.6 M | 9.6 M | 9.6 M | 9.6 M | 16.8 M | 43.2 M | 57.8 M | 91.9 M | 148.2 M | 155.6 M |
| GLUE | 7.3 M | 7.3 M | 7.3 M | 7.3 M | 7.3 M | 7.3 M | 7.3 M | 7.3 M | 7.3 M | 7.3 M | 24 M | 57.2 M | 85.1 M | 111.3 M | 62.7 M |
| RVMD | 26.6 M | 26.6 M | 26.6 M | 26.6 M | 26.6 M | 26.6 M | 26.6 M | 26.6 M | 51.1 M | 91.8 M | 132.3 M | 186.9 M | 253.1 M | 423.1 M | 444.3 M |
| REVB | 2.6 K | 2.6 K | 2.6 K | 2.6 K | 2.6 K | 2.6 K | 2.6 K | 2.6 K | 2.6 K | 2.6 K | 2.6 K | 6.9 M | 5.4 M | 4.1 M | 4.5 M |
| ZURA | 23.7 M | 23.7 M | 23.7 M | 23.7 M | 23.7 M | 23.7 M | 23.7 M | 23.7 M | 23.7 M | 23.7 M | 23.7 M | 23.7 M | 23.7 M | 44 M | 37.2 M |
| PHIO | 6.6 M | 6.6 M | 10.5 M | 17.7 M | 5.7 M | 6.9 M | 5.4 M | 5.4 M | 4.3 M | 4.3 M | 4.4 M | 8.9 M | 7 M | 6.3 M | 5.7 M |
| RNAZ | 226.3 K | 226.3 K | 226.3 K | 226.3 K | 226.3 K | 226.3 K | 226.3 K | 226.3 K | 226.3 K | 226.3 K | 284.5 K | 2.8 M | 10.2 M | 12.3 M | 12.9 M |
Evaxion Biotech AS and related stocks such as Sigilon Therapeutics, Reviva Pharmaceuticals, and ZyVersa Therapeutics Research Development description
My Equities
My Current Equities and Potential Positions
| Evaxion Biotech AS | EVAX |
Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Location | Denmark |
| Exchange | NASDAQ Exchange |
USD 1.66
Additional Tools for Evaxion Stock Analysis
When running Evaxion Biotech's price analysis, check to measure Evaxion Biotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Evaxion Biotech is operating at the current time. Most of Evaxion Biotech's value examination focuses on studying past and present price action to predict the probability of Evaxion Biotech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Evaxion Biotech's price. Additionally, you may evaluate how the addition of Evaxion Biotech to your portfolios can decrease your overall portfolio volatility.